Ticagrelor: Uses, Dosage, Side Effects & Brands | MedexInfo

Ticagrelor

Rx

Generic NameTicagrelor

Therapeutic ClassAntiplatelet Agent (P2Y12 receptor inhibitor)

Common Dose90 mg twice daily

Max / 24h180 mg

PregnancyUse only if clearly needed

Indications ▼

Acute Coronary Syndrome (STEMI, NSTEMI, unstable angina)

Prevention of thrombotic cardiovascular events after myocardial infarction

Used in combination with low-dose aspirin

Mechanism & Pharmacokinetics ▼

Mechanism: Ticagrelor is a reversible, direct-acting P2Y12 receptor antagonist that inhibits ADP-mediated platelet aggregation.

Pharmacokinetics: Rapid oral absorption, peak plasma concentration ~1.5 hours. Metabolized via CYP3A4. Half-life ~7–12 hours. Excreted mainly via feces.

Dosage & Administration ▼

Indication	Dose	Frequency
Acute Coronary Syndrome	180 mg loading dose, then 90 mg	Twice daily
Post-MI or high-risk ACS	60–90 mg	Twice daily

Note: Always co-administer with low-dose aspirin (≤100 mg/day). Avoid abrupt discontinuation to reduce thrombotic risk.

Side Effects ▼

Dyspnea (shortness of breath)

Bleeding (minor or major)

Bradyarrhythmia (rare)

Headache, dizziness

Gastrointestinal discomfort (nausea, diarrhea)

Contraindications ▼

Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)

History of intracranial hemorrhage

Severe hepatic impairment

Hypersensitivity to ticagrelor

Drug Interaction ▼

Strong CYP3A4 inhibitors: increase ticagrelor levels, risk of bleeding

Strong CYP3A4 inducers: reduce efficacy

Other antiplatelets or anticoagulants: increased bleeding risk

High-dose aspirin (>100 mg/day) reduces ticagrelor effectiveness

Pregnancy & Lactation ▼

Use only if clearly needed; limited human data

Breastfeeding not recommended due to potential bleeding risk in infant

Clinical / Research Summary ▼

Clinical Role: First-line P2Y12 inhibitor in ACS for preventing thrombotic events.

Advantage: Faster, reversible platelet inhibition compared to clopidogrel.

Monitoring: Bleeding signs, heart rate (for bradyarrhythmia), liver function.

Research Focus: Long-term cardiovascular protection post-ACS, bleeding risk reduction strategies.

Patient Counseling Points ▼

Take twice daily with or without food

Do not stop abruptly; consult physician before discontinuation

Report unusual bleeding or bruising immediately

Avoid high-dose aspirin unless prescribed

Storage & Handling ▼

Store below 30°C

Protect from moisture and light

Keep container tightly closed

Brand Names (Bangladesh & Global) ▼

Bangladesh:

Acora® 90 mg Belinta® 90 mg Belinta® 60 mg Brirel® 90 mg Gleron® 90 mg Plarit® 90 mg Ticacard® 90 mg Ticaflow® 60 mg Ticaflow® 90 mg Ticalog® 90 mg Ticarel® 60 mg Ticarel® 90 mg Tiga® 60 mg Tiga® 90 mg Tigel® 90 mg

Global:

Brilinta

Medical Disclaimer: For educational purposes only. Not a substitute for professional medical advice.

Reference Hubs:

• Drug Class: Antiplatelet Agents • Condition: Acute Coronary Syndrome • Condition: Myocardial Infarction